Synlogic SYBX Stock
Synlogic Price Chart
Synlogic SYBX Financial and Trading Overview
| Synlogic stock price | 1.77 USD |
| Previous Close | 0.57 USD |
| Open | 0.55 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 900 |
| Day's Range | 0.54 - 0.57 USD |
| 52 Week Range | 0.45 - 1.35 USD |
| Volume | 75.94K USD |
| Avg. Volume | 328.49K USD |
| Market Cap | 38.49M USD |
| Beta (5Y Monthly) | 1.026056 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.81 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.75 USD |
SYBX Valuation Measures
| Enterprise Value | 657.54K USD |
| Trailing P/E | N/A |
| Forward P/E | -0.64862067 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 34.67715 |
| Price/Book (mrq) | 0.5587129 |
| Enterprise Value/Revenue | 0.592 |
| Enterprise Value/EBITDA | -0.01 |
Trading Information
Synlogic Stock Price History
| Beta (5Y Monthly) | 1.026056 |
| 52-Week Change | -45.76% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.35 USD |
| 52 Week Low | 0.45 USD |
| 50-Day Moving Average | 0.57 USD |
| 200-Day Moving Average | 0.77 USD |
SYBX Share Statistics
| Avg. Volume (3 month) | 328.49K USD |
| Avg. Daily Volume (10-Days) | 240.62K USD |
| Shares Outstanding | 68.21M |
| Float | 46.76M |
| Short Ratio | 0.73 |
| % Held by Insiders | 16.63% |
| % Held by Institutions | 51.31% |
| Shares Short | 491.15K |
| Short % of Float | 1.08% |
| Short % of Shares Outstanding | 0.72% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:7 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -6116.84% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -33.57% |
| Return on Equity (ttm) | -65.74% |
Income Statement
| Revenue (ttm) | 1.11M USD |
| Revenue Per Share (ttm) | 0.02 USD |
| Quarterly Revenue Growth (yoy) | -28.69% |
| Gross Profit (ttm) | 1.18M USD |
| EBITDA | -65402000 USD |
| Net Income Avi to Common (ttm) | -66072000 USD |
| Diluted EPS (ttm) | -0.93 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 57.37M USD |
| Total Cash Per Share (mrq) | 0.84 USD |
| Total Debt (mrq) | 19.3M USD |
| Total Debt/Equity (mrq) | 28.09 USD |
| Current Ratio (mrq) | 6.404 |
| Book Value Per Share (mrq) | 1.01 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -62916000 USD |
| Levered Free Cash Flow (ttm) | -37921876 USD |
Profile of Synlogic
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 301 Binney Street |
| ZIP | 02142 |
| Phone | 617 401 9975 |
| Website | https://www.synlogictx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 72 |
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
Q&A For Synlogic Stock
What is a current SYBX stock price?
Synlogic SYBX stock price today per share is 1.77 USD.
How to purchase Synlogic stock?
You can buy SYBX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Synlogic?
The stock symbol or ticker of Synlogic is SYBX.
Which industry does the Synlogic company belong to?
The Synlogic industry is Biotechnology.
How many shares does Synlogic have in circulation?
The max supply of Synlogic shares is 11.65M.
What is Synlogic Price to Earnings Ratio (PE Ratio)?
Synlogic PE Ratio is now.
What was Synlogic earnings per share over the trailing 12 months (TTM)?
Synlogic EPS is -8.81 USD over the trailing 12 months.
Which sector does the Synlogic company belong to?
The Synlogic sector is Healthcare.
Synlogic SYBX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}